Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
Mayer, Katharina A, Budde, Klemens, Halloran, Philip F, Doberer, Konstantin, Rostaing, Lionel, Eskandary, Farsad, Christamentl, Anna, Wahrmann, Markus, Regele, Heinz, Schranz, Sabine, Ely, Sarah, Firbas, Christa, Schörgenhofer, Christian, Kainz, Alexander, Loupy, Alexandre, Härtle, Stefan, Boxhammer, Rainer, Jilma, Bernd, Böhmig, Georg A
Published in Current controlled trials in cardiovascular medicine (08.04.2022)
Published in Current controlled trials in cardiovascular medicine (08.04.2022)
Get full text
Journal Article
425 Felzartamab (anti-CD38) in patients with IgA Nephropathy—interim results from the IGNAZ study
Floege, Jürgen, Lafayette, Richard, Barratt, Jonathan, Schwartz, Brian, Manser, Paul T, Patel, Uptal D, Pineda, Lilia, Faulhaber, Nicola, Boxhammer, Rainer, Haertle, Stefan, Thakur, Anjali, Barbour, Sean
Published in Nephrology, dialysis, transplantation (23.05.2024)
Published in Nephrology, dialysis, transplantation (23.05.2024)
Get full text
Journal Article
Felzartamab Reduces aPLA2R Ab by Selectively Depleting CD38+ Plasma Cells and Plasmablasts, the Main Pathogenic Cellular Drivers of Disease in Primary Membranous Nephropathy (PMN): SA-PO910
Flesher, Donna, Boxhammer, Rainer, Kräft, Tabea, Kivman, Lisa, Haertle, Stefan, Dudani, Jaideep, Gilbert, Houston N., Patel, Uptal D., Rovin, Brad H.
Published in Journal of the American Society of Nephrology (01.11.2023)
Published in Journal of the American Society of Nephrology (01.11.2023)
Get full text
Journal Article
Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
Her, Jung Hyun, Pretscher, Dominik, Patra-Kneuer, Maria, Schanzer, Juergen, Cho, Sung Yoo, Hwang, Yu Kyeong, Hoeres, Timm, Boxhammer, Rainer, Heitmueller, Christina, Wilhelm, Martin, Steidl, Stefan, Endell, Jan
Published in Cancer Immunology, Immunotherapy (01.11.2022)
Published in Cancer Immunology, Immunotherapy (01.11.2022)
Get full text
Journal Article
Safety and Efficacy of Felzartamab in Primary Membranous Nephropathy (PMN): Final Analysis of the M-PLACE Study: TH-OR27
Rovin, Brad H., Ronco, Pierre M., Wetzels, Jack F., Adler, Sharon G., Ayoub, Isabelle, Han, Seung Hyeok, Dudani, Jaideep, Gilbert, Houston N., Patel, Uptal D., Jauch-Lembach, Julia, Faulhaber, Nicola, Boxhammer, Rainer, Haertle, Stefan, Sprangers, Ben
Published in Journal of the American Society of Nephrology (01.11.2023)
Published in Journal of the American Society of Nephrology (01.11.2023)
Get full text
Journal Article
Felzartamab in Patients with Anti-Phospholipase A2 Receptor Autoantibody Positive (Anti-PLA2R+) Membranous Nephropathy (MN): Interim Results from the M-PLACE Study: PO1647
Rovin, Brad H., Adler, Sharon G., Hoxha, Elion, Sprangers, Ben, Stahl, Rolf A., Wetzels, Jack F., Schwamb, Bettina, Boxhammer, Rainer, Nguyen, Quynh, Haertle, Stefan, Ronco, Pierre M.
Published in Journal of the American Society of Nephrology (01.10.2021)
Published in Journal of the American Society of Nephrology (01.10.2021)
Get full text
Journal Article
Immunologic Responses Following COVID-19 Vaccination in Patients with Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results from the Phase 1b/2a M-PLACE Study
Rovin, Brad H, Boxhammer, Rainer, Thakur, Anjali, Ronco, Pierre M
Published in Kidney international reports (10.06.2022)
Get full text
Published in Kidney international reports (10.06.2022)
Journal Article
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
Mayer, Katharina A., Schrezenmeier, Eva, Diebold, Matthias, Halloran, Philip F., Schatzl, Martina, Schranz, Sabine, Haindl, Susanne, Kasbohm, Silke, Kainz, Alexander, Eskandary, Farsad, Doberer, Konstantin, Patel, Uptal D., Dudani, Jaideep S., Regele, Heinz, Kozakowski, Nicolas, Kläger, Johannes, Boxhammer, Rainer, Amann, Kerstin, Puchhammer-Stöckl, Elisabeth, Vietzen, Hannes, Beck, Julia, Schütz, Ekkehard, Akifova, Aylin, Firbas, Christa, Gilbert, Houston N., Osmanodja, Bilgin, Halleck, Fabian, Jilma, Bernd, Budde, Klemens, Böhmig, Georg A.
Published in The New England journal of medicine (11.07.2024)
Published in The New England journal of medicine (11.07.2024)
Get full text
Journal Article
Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)
Her, Jung Hyun, Pretscher, Dominik, Cho, Sungyoo, Hwang, Yu-Kyeong, Hoeres, Timm, Boxhammer, Rainer, Steidl, Stefan, Patra, Maria, Schanzer, Juergen, Endell, Jan
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide
Mougiakakos, Dimitrios, Voelkl, Simon, Bach, Christian, Stoll, Andrej, Bitterer, Katrin, Beier, Fabian, Endell, Jan, Boxhammer, Rainer, Bittenbring, Jörg Thomas, Mackensen, Andreas, Bruns, Heiko
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Busch, Leonhard, Mougiakakos, Dimitrios, Büttner-Herold, Maike, Müller, Miriam J., Volmer, Dietrich A., Bach, Christian, Fabri, Mario, Bittenbring, Jörg T., Neumann, Frank, Boxhammer, Rainer, Nolting, Jens, Bisht, Savita, Böttcher, Martin, Jitschin, Simon, Hoffmann, Markus H., Balzer, Heidi, Beier, Fabian, Gezer, Deniz, Dudziak, Diana, Gelse, Kolja, Hennig, Friedrich F., Pallasch, Christian P., Spriewald, Bernd, Mackensen, Andreas, Bruns, Heiko
Published in Leukemia (01.11.2018)
Published in Leukemia (01.11.2018)
Get full text
Journal Article